{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:04:57Z","timestamp":1784804697916,"version":"3.55.0"},"reference-count":64,"publisher":"Rambam Health Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"DOI":"10.5041\/rmmj.10279","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T04:02:24Z","timestamp":1485748944000},"page":"e0004","source":"Crossref","is-referenced-by-count":34,"title":["Comorbidities in Patients with Psoriatic Arthritis"],"prefix":"10.5041","volume":"8","author":[{"given":"Amir","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devy","family":"Zisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2017,1,30]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","article-title":"Comorbidities in psoriatic arthritis","volume":"41","author":"Husni","year":"2015","unstructured":"1. Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am 2015;41:677-98.","journal-title":"Rheum Dis Clin North Am"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","unstructured":"2. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-7.","journal-title":"Exp Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2013.06.053","article-title":"Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors","volume":"69","author":"Miller","year":"2013","unstructured":"3. Miller I, Ellervik C, Yazdanyar S, Jemec G. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013; 69:1014-24.","journal-title":"J Am Acad Dermatol"},{"key":"ref3","unstructured":"4. Han C, Robinson D Jr, Hackett M, Paramore L, Fraeman K, Bala M. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2008.094839","article-title":"Cardiovascular morbidity in psoriatic arthritis","volume":"68","author":"Gladman","year":"2009","unstructured":"5. Gladman D, Ang M, Su L, Tom B, Schentag C, Farewell V. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131-5.","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2014","unstructured":"6. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2014;74:326-32.","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1136\/annrheumdis-2014-205267","article-title":"Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","unstructured":"7. Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis 2015;74:1830-5.","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","unstructured":"8. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","unstructured":"9. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011;306: 864-71.","journal-title":"JAMA"},{"key":"ref9","unstructured":"10. US Food and Drug Administration. FDA Briefing Document: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee on Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Thrombotic Risk. February 10-11, 2014. Available at: http:\/\/bit.ly\/2gvTCgm."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.22185","article-title":"Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis","volume":"66","author":"Labitigan","year":"2014","unstructured":"11. Labitigan M, Bah\u010de-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:600-7.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2011-200567","article-title":"Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence","volume":"71","author":"Johnsson","year":"2012","unstructured":"12. Johnsson H, McInnes IB, Sattar N. Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence. Ann Rheum Dis 2012;71:480-3.","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"169","author":"Coto-Segura","year":"2013","unstructured":"13. Coto-Segura P, Eiris-Salvado N, Gonzalez-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol 2013;169:783-93.","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Armstrong AW, Gu\u00e9rin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol 2015;72:968-77.e2.","DOI":"10.1016\/j.jaad.2015.02.1095"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/ker349","article-title":"Differences in body mass index among individuals with PsA, psoriasis, RA and the general population","volume":"51","author":"Bhole","year":"2012","unstructured":"15. Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 2012;51:552-6.","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","unstructured":"16. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 2014;41:1357-65.","journal-title":"J Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","article-title":"Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation","volume":"47","author":"Tam","year":"2008","unstructured":"17. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford) 2008;47:718-23.","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","unstructured":"18. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-72."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1529-8019.2008.01217.x","article-title":"Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis","volume":"22","author":"Channual","year":"2009","unstructured":"19. Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009;22:61-73.","journal-title":"Dermatol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/oby.2004.24","article-title":"A novel pathway to the manifestations of metabolic syndrome","volume":"12","author":"Sonnenberg","year":"2004","unstructured":"20. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180-6.","journal-title":"Obes Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11892-007-0025-3","article-title":"The search for type 2 diabetes susceptibility loci: the chromosome 1q story","volume":"7","author":"SK","year":"2007","unstructured":"21. Das SK, Elbein SC. The search for type 2 diabetes susceptibility loci: the chromosome 1q story. Curr Diab Rep 2007;7:154-64.","journal-title":"Curr Diab Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.biocel.2007.04.009","article-title":"Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways","volume":"39","author":"Yoo","year":"2007","unstructured":"22. Yoo H, Kim SJ, Kim Y, Lee H, Kim TY. Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways. Int J Biochem Cell Biol 2007;39:1248-59.","journal-title":"Int J Biochem Cell Biol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/jmg.2007.053595","article-title":"Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease","volume":"45","author":"Wolf","year":"2008","unstructured":"23. Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-16.","journal-title":"J Med Genet"},{"key":"ref23","unstructured":"24. Haddad A, Cohen AD, Ashkenazi RI, et al. Endocrine comorbidities in patients with psoriatic arthritis - a population based case controlled study. Oral Presentation, The 2016 GRAPPA Annual Scientific Meeting. Miami, Florida. July 14-16, 2016."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 2004;13:215-28.","DOI":"10.1517\/eoid.13.3.215.27349"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/jid.2013.448","article-title":"Preclinical studies of a specific PPAR\u03b3 modulator in the control of skin inflammation","volume":"134","author":"Mastrofrancesco","year":"2014","unstructured":"26. Mastrofrancesco A, Kovacs D, Sarra M, et al. Preclinical studies of a specific PPAR\u03b3 modulator in the control of skin inflammation. J Invest Dermatol 2014;134:1001-11.","journal-title":"J Invest Dermatol"},{"key":"ref26","unstructured":"27. Rossini M, Viapiana O, Adami S, et al. In patients with rheumatoid arthritis, Dickkopf-1 serum levels and correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol 2015;33:77-83."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/BOR.0b013e3283620777","article-title":"Osteoporosis and vertebral fractures in ankylosing spondylitis","volume":"25","author":"Davey-Ranasinghe N","year":"2013","unstructured":"28. Davey-Ranasinghe N, Deodhar A. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2013;25:509-16.","journal-title":"Curr Opin Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3899\/jrheum.140919","article-title":"Systemic lupus erythematosus, osteoporosis, and fractures","volume":"41","author":"JD","year":"2014","unstructured":"29. Adachi JD, Lau A. Systemic lupus erythematosus, osteoporosis, and fractures. J Rheumatol 2014;41: 1913-15.","journal-title":"J Rheumatol"},{"key":"ref29","unstructured":"30. Omair MA, McDonald-Blumer H, Johnson SR. Bone disease in systemic sclerosis: outcomes and associations. Clin Exp Rheumatol 2014;32(6 Suppl 86):S28-32."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4081\/reumatismo.2014.785","article-title":"Osteoporosis and rheumatic diseases","volume":"66","author":"Maruotti","year":"2014","unstructured":"31. Maruotti N, Corrado A, Cantatore FP. Osteoporosis and rheumatic diseases. Reumatismo 2014;66:125-35.","journal-title":"Reumatismo"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Grazio S, Cvijeti\u0107 S, Vlak T, et al. Osteoporosis in psoriatic arthritis: is there any? Wien Klin Wochenschr 2011;123:743-50.","DOI":"10.1007\/s00508-011-0095-8"},{"key":"ref32","unstructured":"33. Frediani B, Allegri A, Falsetti P, et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001;28:138-43."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/BF02054256","article-title":"Total and peripheral bone mass in patients with psoriatic arthritis and rheumatoid arthritis","volume":"5","author":"Reid","year":"1986","unstructured":"34. Reid DM, Kennedy NS, Nicoll J, Smith MA, Tothill P, Nuki G. Total and peripheral bone mass in patients with psoriatic arthritis and rheumatoid arthritis. Clin Rheumatol 1986;5:372-8.","journal-title":"Clin Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women","volume":"72","author":"WQ","year":"2013","unstructured":"35. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2013;72:1200-5.","journal-title":"Ann Rheum Dis"},{"key":"ref35","unstructured":"36. Scarpa R, Manguso F, D'Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000;27:1241-6."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series","volume":"79","author":"Toussirot","year":"2012","unstructured":"37. Toussirot E, Houvenagel E, Goeb V, et al. Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine 2012;79:457-63.","journal-title":"Joint Bone Spine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/j.1572-0241.2000.02262.x","article-title":"Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study","volume":"95","author":"Felder","year":"2000","unstructured":"38. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000;95: 1949-54.","journal-title":"Am J Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/ard.35.4.354","article-title":"Eye inflammation in psoriatic arthritis","volume":"35","author":"JR","year":"1976","unstructured":"39. Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis 1976;35:354-6.","journal-title":"Ann Rheum Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/00006982-200310000-00022","article-title":"Posterior scleritis in psoriatic arthritis","volume":"23","author":"Altan-Yaycioglu","year":"2003","unstructured":"40. Altan-Yaycioglu R, Akova YA, Kart H, Cetinkaya A, Yilmaz G, Aydin P. Posterior scleritis in psoriatic arthritis. Retina 2003;23:717-19.","journal-title":"Retina"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6061\/clinics\/2012(03)08","article-title":"Prevalence of eye disease in Brazilian patients with psoriatic arthritis","volume":"67","author":"Lima","year":"2012","unstructured":"41. Lima FB, Abalem MF, Ruiz DG, et al. Prevalence of eye disease in Brazilian patients with psoriatic arthritis. Clinics (Sao Paulo) 2012;67:249-53.","journal-title":"Clinics (Sao Paulo)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","unstructured":"42. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008;67:955-9.","journal-title":"Ann Rheum Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","unstructured":"43. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23.","journal-title":"Arthritis Rheum"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","unstructured":"44. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52.","journal-title":"Arthritis Rheum"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45. Mellemkjaer L, Linet MS, Gridley G, Frisch M, M\u00f8ller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.","DOI":"10.1016\/0959-8049(96)00210-9"},{"key":"ref45","unstructured":"46. Bernatsky S, Boivin J-F, Clarke A, Rajan R. Cancer risk in systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2001;44(Suppl 9):S244."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/ard.52.7.531","article-title":"Scleroderma and malignancy: an epidemiological study","volume":"52","author":"Rosenthal","year":"1993","unstructured":"47. Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993;52:531-3.","journal-title":"Ann Rheum Dis"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis","volume":"326","author":"Sigurgeirsson","year":"1992","unstructured":"48. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 1992;326:363-7.","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","unstructured":"49. Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48-58.","journal-title":"Arthritis Rheum"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","unstructured":"50. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64:1035-50.","journal-title":"J Am Acad Dermatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1440-0960.2012.00905.x","article-title":"The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India","volume":"53","author":"Madanagobalane","year":"2012","unstructured":"51. Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012;53:190-7.","journal-title":"Australas J Dermatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","unstructured":"52. Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide. Ann Rheum Dis 2010; 69:43-7.","journal-title":"Ann Rheum Dis"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00044011-200626020-00001","article-title":"Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis","volume":"26","author":"Tilling","year":"2006","unstructured":"53. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006;26:55-62.","journal-title":"Clin Drug Investig"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","article-title":"Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Miele","year":"2009","unstructured":"54. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:778-86.","journal-title":"J Hepatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1136\/ard.2009.116194","article-title":"Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study","volume":"69","author":"Seitz","year":"2010","unstructured":"55. Seitz M, Reichenbach S, Moller B, Zwahlen M, Villiger PM, Dufour JF. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 2010;69:1148-50.","journal-title":"Ann Rheum Dis"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/rheumatology\/kep176","article-title":"Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate","volume":"48","author":"Amital","year":"2009","unstructured":"56. Amital H, Arnson Y, Chodick G, Shalev V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009;48:1107-10.","journal-title":"Rheumatology (Oxford)"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","unstructured":"57. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-18.","journal-title":"J Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","unstructured":"58. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.","journal-title":"J Am Acad Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pnpbp.2014.01.013","article-title":"Inflamed moods: a review of the interactions between inflammation and mood disorders","volume":"53","author":"Rosenblat","year":"2014","unstructured":"59. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014;53:23-34.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis","volume":"134","author":"Dowlatshahi","year":"2014","unstructured":"60. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 2014; 134:1542-51.","journal-title":"J Invest Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","unstructured":"61. McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 2014;41:887-96.","journal-title":"J Rheumatol"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"62. Wu CY, Chang YT, Juan CK, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore) 2016;95:e3816.","DOI":"10.1097\/MD.0000000000003816"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"762921","DOI":"10.1155\/2013\/762921","article-title":"High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study","volume":"2013","author":"Magrey","year":"2013","unstructured":"63. Magrey MN, Antonelli M, James N, Khan MA. High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study. Arthritis 2013;2013:762921.","journal-title":"Arthritis"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.151491","article-title":"The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study","volume":"43","author":"Brikman","year":"2016","unstructured":"64. Brikman S, Furer V, Wollman J, et al. The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 2016;43: 1749-54.","journal-title":"J Rheumatol"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/619\/1\/PublishFiles\/647Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:36:54Z","timestamp":1784803014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/32\/Articles\/647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,30]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,30]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10279","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,30]]}}}